Literature DB >> 2403401

Autoantibodies to nonhistone chromosomal proteins HMG-1 and HMG-2 in sera of patients with juvenile rheumatoid arthritis.

B Wittemann1, G Neuer, H Michels, H Truckenbrodt, F A Bautz.   

Abstract

IgG antibodies against the high mobility group (HMG) nonhistone chromosomal proteins HMG-1 and/or HMG-2 were detected in the sera of 49 (39%) of 126 antinuclear antibody (ANA)-positive patients with juvenile rheumatoid arthritis (JRA), by immunoblotting. Clinical diagnosis classified these patients in 2 major groups, 105 with pauciarticular-onset JRA and 21 with polyarticular-onset JRA. Anti-HMG-1 and/or anti-HMG-2 antibodies were found in 8 (25%) of 32 pauciarticular-onset JRA patients with uveitis and in 34 (47%) of 73 patients without uveitis, whereas anti-HMG-1 and/or anti-HMG-2 antibodies were found in 4 (24%) of 17 children with polyarticular-onset JRA without uveitis. Among 53 sera from ANA-negative JRA patients, 3 (6%) were positive for anti-HMG-1 and/or anti-HMG-2 antibodies, whereas no reactivity to HMG-1 or HMG-2 proteins was observed in 48 sera from age-matched children with nonrheumatic diseases.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2403401     DOI: 10.1002/art.1780330910

Source DB:  PubMed          Journal:  Arthritis Rheum        ISSN: 0004-3591


  24 in total

Review 1.  HMGB1: a multifunctional alarmin driving autoimmune and inflammatory disease.

Authors:  Helena Erlandsson Harris; Ulf Andersson; David S Pisetsky
Journal:  Nat Rev Rheumatol       Date:  2012-01-31       Impact factor: 20.543

Review 2.  Antinuclear antibodies and juvenile chronic arthritis (JCA): search for a specific autoantibody associated with JCA.

Authors:  T R Southwood; P N Malleson
Journal:  Ann Rheum Dis       Date:  1991-09       Impact factor: 19.103

3.  HMG2 interacts with the nucleosome assembly protein SET and is a target of the cytotoxic T-lymphocyte protease granzyme A.

Authors:  Zusen Fan; Paul J Beresford; Dong Zhang; Judy Lieberman
Journal:  Mol Cell Biol       Date:  2002-04       Impact factor: 4.272

4.  Glycyrrhizin attenuates HMGB1-induced hepatocyte apoptosis by inhibiting the p38-dependent mitochondrial pathway.

Authors:  Geum-Youn Gwak; Tae Gun Moon; Dong Ho Lee; Byung Chul Yoo
Journal:  World J Gastroenterol       Date:  2012-02-21       Impact factor: 5.742

Review 5.  Low dosages: new chemotherapeutic weapons on the battlefield of immune-related disease.

Authors:  Jing Liu; Jie Zhao; Liang Hu; Yuchun Cao; Bo Huang
Journal:  Cell Mol Immunol       Date:  2011-03-21       Impact factor: 11.530

6.  RAGE-independent autoreactive B cell activation in response to chromatin and HMGB1/DNA immune complexes.

Authors:  Ana M Avalos; Kerstin Kiefer; Jane Tian; Sean Christensen; Mark Shlomchik; Anthony J Coyle; Ann Marshak-Rothstein
Journal:  Autoimmunity       Date:  2010-02       Impact factor: 2.815

Review 7.  High-mobility group box 1 (HMGB1) in childhood: from bench to bedside.

Authors:  Valeria Chirico; Antonio Lacquaniti; Vincenzo Salpietro; Caterina Munafò; Maria Pia Calabrò; Michele Buemi; Teresa Arrigo; Carmelo Salpietro
Journal:  Eur J Pediatr       Date:  2014-05-09       Impact factor: 3.183

8.  Pathogenic anti-DNA antibodies modulate gene expression in mesangial cells: involvement of HMGB1 in anti-DNA antibody-induced renal injury.

Authors:  Xiaoping Qing; Milena Pitashny; David B Thomas; Franck J Barrat; Mark P Hogarth; Chaim Putterman
Journal:  Immunol Lett       Date:  2008-09-24       Impact factor: 3.685

9.  The putative oncoprotein DEK, part of a chimera protein associated with acute myeloid leukaemia, is an autoantigen in juvenile rheumatoid arthritis.

Authors:  H Sierakowska; K R Williams; I S Szer; W Szer
Journal:  Clin Exp Immunol       Date:  1993-12       Impact factor: 4.330

Review 10.  HMGB1 in health and disease.

Authors:  Rui Kang; Ruochan Chen; Qiuhong Zhang; Wen Hou; Sha Wu; Lizhi Cao; Jin Huang; Yan Yu; Xue-Gong Fan; Zhengwen Yan; Xiaofang Sun; Haichao Wang; Qingde Wang; Allan Tsung; Timothy R Billiar; Herbert J Zeh; Michael T Lotze; Daolin Tang
Journal:  Mol Aspects Med       Date:  2014-07-08
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.